Disclosing clinical trial results: publicity, significance and independence.
Liao
S Matthew
SM
Program on the Ethics of the New Biosciences, James Martin 21st Century School/Faculty of Philosophy, University of Oxford, 16/17 St. Ebbes Street, Oxford, United Kingdom. matthew.liao@philosophy.ox.ac.uk
Sheehan
Mark
M
Clarke
Steve
S
D002986:Clinical Trials as Topic / Q000941:ethics* / Q000331:legislation & jurisprudence; D003132:Commerce; D003219:Confidentiality / Q000941:ethics / Q000331:legislation & jurisprudence; D016265:Conflict of Interest / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000941:ethics* / Q000331:legislation & jurisprudence; D026689:Ethical Analysis; D028744:Ethics Committees, Research; D006801:Humans; D007258:Informed Consent / Q000941:ethics*; D016365:Liability, Legal; D028681:Moral Obligations; D012108:Research Personnel; D035842:Research Subjects; D035844:Researcher-Subject Relations / Q000941:ethics*; D012945:Social Values; D016896:Treatment Outcome; D014342:Truth Disclosure / Q000941:ethics*; D014481:United States; D014486:United States Food and Drug Administration